They add a pathway that no approved metabolic peptide currently engages, which is what makes them scientifically compelling and also exactly why they remain investigational
What the conversation covers Unique challenges in type 1 diabetes , why insulin alone has structural limitations The mechanism , how GLP-1 therapies work The evidence in type 1 diabetes , from early studies to ADJUST T1D and tirzepatide Exploration points , what the evidence tends to show on insulin adjustment, monitoring, and nutrition Future directions , triple and quadruple agonists, reimbursement, and paediatric potential Watch or listen Key themes Why insulin alone has structural limitations The episode opens by exploring why insulin alone has structural limitations in type 1 diabetes
Additionally, NRF2 activation suppresses angiogenesis by inducing autophagy in vascular endothelial cells, thereby disrupting the energy supply to cancer cells (230)
Bin chng bnh vng mc tiu ng c bo co bnh nhn i tho ng type 2 dng semaglutide
Obesity and Weight Management Research The primary focus of cagrilintide research has been its profound effects on body weight reduction [9] : Key Clinical Trial Data - Phase 2 ONWARDS 1 Design: 32-week, dose-ranging study in 706 adults with overweight/obesity Results (Cagrilintide monotherapy): [9] 0.3 mg weekly: -3.9% weight loss 0.6 mg weekly: -6.0% weight loss 1.2 mg weekly: -8.1% weight loss 2.4 mg weekly: -10.8% weight loss 4.5 mg weekly: -10.4% weight loss Mechanism: Weight loss attributed primarily to reduced energy intake (-535 kcal/day at 2.4 mg dose) rather than increased energy expenditure Research Implications: Cagrilintide provides a valuable research tool for investigating amylin receptor-mediated satiety pathways independent of GLP-1 signaling, offering insights into hormone-specific contributions to appetite regulation
